Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

EXACT Therapeutics AS: Primary insider notification

EXACT Therapeutics
In connection with the re-election of Jonathan Allis to the board of directors
of EXACT Therapeutics AS ("EXACT-Tx" or the "Company"), Jonathan Allis has been
granted 569,370 options in the Company which will vest on a quarterly basis.
With the addition of the 63,263 options previously granted, Mr. Allis now has a
total of 632,633 options.
Please see the attached notification form for further information.

This information is subject to the disclosure requirements in section 5-12 of
the Norwegian Securities Trading Act.

For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
Email per.walday@exact-tx.com

About EXACT-Tx:
EXACT-Tx is a clinical-stage precision medicine company utilizing the power of
ultrasound and microbubbles to enable targeted drug delivery in oncology.
Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to
a wide range of therapeutic agents across a multitude of indications including
within oncology (chemotherapy, immunotherapy) and brain diseases.
www.exact-tx.com
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.